📊 EW Key Takeaways
Is Edwards Lifesciences Corp (EW) a Good Investment?
Edwards Lifesciences demonstrates exceptional fundamental strength with best-in-class profitability (78% gross margin, 20.8% operating margin) and fortress-like balance sheet (0.06x debt/equity, 3.72x current ratio). The company generates substantial free cash flow ($1.3B, 22% FCF margin) with minimal leverage, positioning it as a low-risk, high-quality compounder in the medical devices sector.
Edwards Lifesciences shows high-quality fundamentals with strong gross margins, solid operating profitability, robust free cash flow generation, and a very conservative balance sheet. Liquidity is excellent and leverage is low, which supports resilience and strategic flexibility. However, the extreme revenue growth figure and sharp EPS decline alongside flat net income suggest comparability or one-time-item distortion, so the underlying growth trend needs confirmation before a more aggressive rating is justified.
Why Buy Edwards Lifesciences Corp Stock? EW Key Strengths
- Industry-leading gross margin of 78% indicates strong pricing power and operational efficiency
- Exceptional balance sheet health with 0.06x debt/equity ratio and $2.9B cash providing substantial financial flexibility
- Robust free cash flow generation of $1.3B with 22% FCF margin demonstrates sustainable earnings quality
- Strong interest coverage of 71.8x and liquidity ratios (3.72x current, 3.09x quick) indicate zero financial distress risk
- Consistent profitability with 17.7% net margin across challenging medical device environment
- High profitability with 78.0% gross margin, 20.8% operating margin, and 17.7% net margin
- Strong financial health driven by $2.94B cash, 3.72x current ratio, and very low 0.06x debt-to-equity
- Healthy cash generation with $1.33B free cash flow and a 22.0% FCF margin
EW Stock Risks: Edwards Lifesciences Corp Investment Risks
- Extreme YoY revenue growth of 29,843% appears anomalous and warrants investigation into one-time items or accounting changes affecting comparability
- EPS diluted down 73.7% YoY despite net income near-flat suggests significant share dilution or acquisition-related equity issuance
- Modest ROE of 10.4% and ROA of 7.8% lag expectations for such high-margin business, indicating potential asset inefficiency or recent capital deployment
- Capital-intensive medical device industry may require sustained CapEx (currently $260M) limiting future cash return flexibility
- 11 Form 4 insider filings in 90 days without directional context could indicate uncertainty or routine executive trading patterns
- Revenue growth of +29843.1% appears abnormal and may reflect reporting distortion or a non-recurring event
- Diluted EPS fell 73.7% year over year despite stable net income, raising questions about earnings quality or share count effects
- ROE of 10.4% is respectable but not exceptional relative to the company’s large equity base
Key Metrics to Watch
- Organic revenue growth rate normalized for one-time items (current 29,843% YoY clearly anomalous)
- Share dilution trends and acquisition-related charges impacting EPS accretion going forward
- Operating cash flow sustainability and working capital efficiency (currently $1.6B OCF)
- Return on equity trajectory toward industry benchmarks as capital integration matures
- Capital expenditure as percentage of revenue and free cash flow yield to shareholders
- Normalized organic revenue growth and segment-level sales trends
- Diluted EPS progression relative to net income and free cash flow
Edwards Lifesciences Corp (EW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 22.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.72x current ratio provides a solid financial cushion.
EW Profit Margin, ROE & Profitability Analysis
EW vs Healthcare Sector: How Edwards Lifesciences Corp Compares
How Edwards Lifesciences Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Edwards Lifesciences Corp Stock Overvalued? EW Valuation Analysis 2026
Based on fundamental analysis, Edwards Lifesciences Corp appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Edwards Lifesciences Corp Balance Sheet: EW Debt, Cash & Liquidity
EW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Edwards Lifesciences Corp's revenue has grown significantly by 16% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.30 reflects profitable operations.
EW Revenue Growth, EPS Growth & YoY Performance
EW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4B | $291.1M | $0.50 |
| Q2 2025 | $1.4B | $333.2M | $0.56 |
| Q1 2025 | $1.3B | $351.9M | $0.58 |
| Q3 2024 | $1.2B | $384.9M | $0.63 |
| Q2 2024 | $1.3B | $307.1M | $0.50 |
| Q1 2024 | $1.5B | $340.5M | $0.56 |
| Q3 2023 | $1.3B | $343.5M | $0.55 |
| Q2 2023 | $1.4B | $307.1M | $0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Edwards Lifesciences Corp Dividends, Buybacks & Capital Allocation
EW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Edwards Lifesciences Corp (CIK: 0001099800)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EW
What is the AI rating for EW?
Edwards Lifesciences Corp (EW) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (HOLD) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EW's key strengths?
Claude: Industry-leading gross margin of 78% indicates strong pricing power and operational efficiency. Exceptional balance sheet health with 0.06x debt/equity ratio and $2.9B cash providing substantial financial flexibility. ChatGPT: High profitability with 78.0% gross margin, 20.8% operating margin, and 17.7% net margin. Strong financial health driven by $2.94B cash, 3.72x current ratio, and very low 0.06x debt-to-equity.
What are the risks of investing in EW?
Claude: Extreme YoY revenue growth of 29,843% appears anomalous and warrants investigation into one-time items or accounting changes affecting comparability. EPS diluted down 73.7% YoY despite net income near-flat suggests significant share dilution or acquisition-related equity issuance. ChatGPT: Revenue growth of +29843.1% appears abnormal and may reflect reporting distortion or a non-recurring event. Diluted EPS fell 73.7% year over year despite stable net income, raising questions about earnings quality or share count effects.
What is EW's revenue and growth?
Edwards Lifesciences Corp reported revenue of $6.1B.
Does EW pay dividends?
Edwards Lifesciences Corp does not currently pay dividends.
Where can I find EW SEC filings?
Official SEC filings for Edwards Lifesciences Corp (CIK: 0001099800) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EW's EPS?
Edwards Lifesciences Corp has a diluted EPS of $1.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Edwards Lifesciences Corp has a BUY rating with 85% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is EW stock overvalued or undervalued?
Valuation metrics for EW: ROE of 10.4% (sector avg: 15%), net margin of 17.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EW stock in 2026?
Our dual AI analysis gives Edwards Lifesciences Corp a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is EW's free cash flow?
Edwards Lifesciences Corp's operating cash flow is $1.6B, with capital expenditures of $260.2M. FCF margin is 22.0%.
How does EW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 17.7% (avg: 12%), ROE 10.4% (avg: 15%), current ratio 3.72 (avg: 2).